From anecdotal evidence of cannabinoids in multiple sclerosis to emerging new therapeutical approaches

Multiple Sclerosis

Volumn 13, Issue 1, 2007, Pages 133-134

  Bifulco, Mau ^a   Laezza, C ^a   Malfitano, A M ^a  

^a UNIVERSITY OF SALERNO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANANDAMIDE; ARVANIL; CANNABIDIOL; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID DERIVATIVE; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; CANNABIS; CANNABIS DERIVATIVE; CAPSAICIN; CYTOKINE; ENDOCANNABINOID; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; VANILLOID RECEPTOR 1;

ALLERGIC ENCEPHALOMYELITIS; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; AUTOIMMUNE DISEASE; DRUG BINDING SITE; DRUG DELIVERY SYSTEM; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; HUMAN; IMMUNOMODULATION; LETTER; LYMPHOCYTE PROLIFERATION; MULTIPLE SCLEROSIS; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; PROTEIN SYNTHESIS INHIBITION; SPASTICITY; TREATMENT PLANNING;

CANNABINOIDS; HUMANS; MULTIPLE SCLEROSIS; PSYCHOTROPIC DRUGS;

EID: 33846526797     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458506071303     Document Type: Letter

References (10)

1. Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 2004; 3: 771-84.
2. Perras C. Sativex for the management of multiple sclerosis symptoms. Issues Emerg Health Technol 2005; 72: 1-4.
3. Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Huffman JW et al. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 2000; 404: 84-87.
4. Di Marzo V, Bifulco M, De Petrocellis L. Endocannabinoids and multiple sclerosis: a blessing from the 'inner bliss'? Trends Pharmacol Sci 2000; 21: 195-97.
5. Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Makriyannis A et al. Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J 2001; 15: 300-302.
6. Eljaschewitsch E, Witting A, Mawrin C, Lee T, Schmidt PM, Wolf S et al. The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron 2006; 49: 4-7.
7. Hemmer B, Cepok S, Nessler S, Sommer N. Pathogenesis of multiple sclerosis: an update on immunology. Curr Opin Neurol 2002; 1: 227-31.
8. Malfitano AM, Matarese G, Bifulco M. From cannabis to endocannabinoids in multiple sclerosis: a paradigm of central nervous system autoimmune diseases. Curr Drug Targets CNS Neurol Disord 2005; 4: 667-75.
9. Brooks JW, Pryce G, Bisogno T, Jaggar SI, Hankey DJ, Brown P et al. Arvanil-induced inhibition of spasticity and persistent pain: evidence for therapeutic site of action different from the vanilloid VR1 and cannabinoid receptor CB(1) CB(2) receptors. Eur J Pharmacol 2002; 439: 83-92.
10. Malfitano AM, Matarese G, Pisanti S, Grimaldi C, Laezza C, Bisogno T et al. Arvanil inhibits T lymphocyte activation and ameliorates autoimmune encephalomyelitis. J Neuroimmunol 2006; 171: 110-19.